<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01549860</url>
  </required_header>
  <id_info>
    <org_study_id>IN-BALANCE VLU</org_study_id>
    <nct_id>NCT01549860</nct_id>
  </id_info>
  <brief_title>Effects of Non Contact Low Frequency Ultrasound in Healing Venous Leg Ulcers</brief_title>
  <official_title>IN-BALANCE VLU Inflammation, Bacteria, &amp; Angiogenesis Effects in Launching Venous Leg Ulcer Healing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celleration, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celleration, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a prospective, randomized, controlled, multi-center study of subjects
      presenting with chronic lower extremity venous ulcers. The study will evaluate the safety and
      effectiveness of MIST Therapy® plus standard of care (MIST+SOC) compared to Standard of Care
      (SOC) alone in the treatment of lower extremity venous ulcers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study compared the treatment effect of non-contact low frequency ultrasound in addition
      to standard of care versus standard of care alone in healing chronic venous leg ulcers in
      subjects who had documented venous stasis and reflux. Subjects that were screened and met the
      major inclusion criteria received standardized treatment of 30 to 40 mmHg compression, moist
      wound healing dressings, and debridement for a two week run-in period. If their study ulcer
      did not decreased by greater than 30% they were eligible for randomization. The primary
      endpoint was wound area reduction after four (4) weeks of study treatment. The study was
      performed at 22 study centers. The study included two sub-studies: fluid and tissue analysis
      and a wound recidivism registry that are ongoing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound Area Mean Percent Reduction</measure>
    <time_frame>4 weeks post baseline visit (randomization visit)</time_frame>
    <description>Compare between the treatment groups percent wound area reduction at four weeks of study treatment.
H0: µMIST+SC -- µSC = 0 HA: µMIST+SC -- µSC ≠ 0 Where µ = percent reduction in wound size.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heal Rates</measure>
    <time_frame>12 weeks post randomization</time_frame>
    <description>Compare rate of wound closure between study arms for 12 weeks post randomization. Descriptive statistics as not a powered endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain VAS Scores</measure>
    <time_frame>Baseline, 2 weeks and 4 weeks post randomization</time_frame>
    <description>Compare VAS Pain Scores between arms at baseline and 4 weeks post randomization
Subjects indicate their pain level by drawing a mark on a 10 cm line on a visual analog scale (VAS) at randomization and 4 week post treatment visit. The left end of the line indicates &quot;no pain&quot; and the right end of line indicates &quot;worst pain imaginable&quot;. VAS score is determined by using a ruler placed at 0 (left end of scale) and measuring the distance from zero to the patient's mark . The objective is to compare the change in VAS values in MIST+SC to SC alone.
H0: The average change in pain level is not different between MIST and SC HA: The average change in pain level is different between MIST and SC H0: µMIST = µSC vs HA: µMIST ≠ µSC,
Statistical Analysis. A repeated measures ANCOVA will be used to test for differences in change in VAS with an indicator variable to indicate treatment, any demographic variables which were significant in the baseline comparisons.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Venous Insufficiency</condition>
  <condition>Venous Reflux</condition>
  <condition>Lower Extremity Ulcer</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed. Minimum of one treatment per week and up to 3 times per week per investigator discretion for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC + Mist Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed plus non-contract low frequency ultrasound 3 x per week for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MIST Therapy</intervention_name>
    <description>Non-contact low frequency ultrasound therapy</description>
    <arm_group_label>SOC + Mist Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lower extremity full thickness venous ulcer of &gt; 30 days duration

          -  Subject's wound must be between 4 cm² and 50 cm² at screening

          -  Documented ABI that is between 0.8 and 1.2 on the study limb or transcutaneous partial
             pressure oxygen (TcpO2) &gt; 40 mmHG; or a toe pressure &gt; 40 mmHG; or a Doppler waveform
             consistent with adequate flow in the foot (biphasic or triphasic waveforms) at time of
             screening

          -  Biopsy for wounds &gt; 6 months duration

          -  Documented index wound etiology of venous stasis with reflux and /or incompetent
             valves

        Exclusion Criteria:

          -  Index ulcer wound that is less than 1 cm in distance from another ulcer wound

          -  &gt; 5 ulcers on the index leg

          -  Index ulcer wound has exposed tendons, ligaments, muscle, or bone

          -  Index ulcer wound presents with clinical signs of acute infection, suspected or known

          -  Subjects with evidence of osteomyelitis or cellulitis or gangrene in the study limb

          -  Subjects with amputation above a Trans Metatarsal Amputation (TMA) in the study limb

          -  Subjects with active malignancy on the study limb except non-melanoma skin cancer

          -  Index ulcer that is of arterial disease etiology

          -  Index ulcer of other primary etiology (ie. vasculitis, arterial, pyoderma)

          -  Subjects with planned vascular surgery, angioplasty or thrombolysis procedures within
             the study treatment phase

          -  Subjects with planned surgical procedure during the study treatment phase for the
             index wound including skin flap or skin graft

          -  Subjects within 6 weeks postoperatively of a vascular o skin graft procedure.

          -  Subject has had prior skin replacement, negative pressure therapy, or traditional
             ultrasound therapy applied to the index wound in the 14 days prior to screening

          -  Subject has had ultrasound treatment (including MIST Therapy) of the index wound.

          -  Subject has received growth factor therapy (e.g., autologous platelet-rich plasma gel,
             becaplermin, bilayered cell therapy, dermal substitute, extracellular matrix) within
             14 days of screening date.

          -  Subject is currently receiving or has received radiation or chemotherapy within 3
             months of randomization.

          -  Female subjects that are pregnant or refuse to utilize adequate contraceptive methods
             and are of childbearing age during the trial.

          -  Subject has one or more medical condition(s), uncontrolled diabetes (i.e. HbA1c &gt; 12),
             renal, hepatic, hematologic, neurologic, or immune disease that in the opinion of the
             investigator would make the subject an inappropriate study candidate

          -  Subject's wound would require ultrasound near an electronic implant or prosthesis

          -  Subject is known to be suffering from a disorder or other situation that the subject
             or investigator feels would interfere with compliance or other study requirements

          -  Subject is currently enrolled or has been enrolled in the last 30 days in another
             investigational device or drug trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Gibbons, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Shore Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vicki Driver, DPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence RI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South Shore Hospital</name>
      <address>
        <city>Weymouth</city>
        <state>Massachusetts</state>
        <zip>02189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2012</study_first_submitted>
  <study_first_submitted_qc>March 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2012</study_first_posted>
  <results_first_submitted>April 27, 2015</results_first_submitted>
  <results_first_submitted_qc>July 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2015</results_first_posted>
  <last_update_submitted>July 2, 2015</last_update_submitted>
  <last_update_submitted_qc>July 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Venous Insufficiency</keyword>
  <keyword>Reflux</keyword>
  <keyword>Lower Extremity Ulcer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Venous Insufficiency</mesh_term>
    <mesh_term>Varicose Ulcer</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>156 subjects were consented for the study, 112 subjects met the major inclusion/exclusion criteria (study cohort), 81 subject were randomized (reduced &lt;30% during run-in period).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Care (SC)</title>
          <description>30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed. Minimum of one treatment per week and up to 3 times per week per investigator discretion for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>SC + Mist Therapy</title>
          <description>30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed plus non-contract low frequency ultrasound 3 x per week for 4 weeks.
MIST Therapy: Non-contact low frequency ultrasound therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Eligible subjects randomized</population>
      <group_list>
        <group group_id="B1">
          <title>Standard Care (SC)</title>
          <description>30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed. Minimum of one treatment per week and up to 3 times per week per investigator discretion for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>SC + Mist Therapy</title>
          <description>30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed plus non-contract low frequency ultrasound 3 x per week for 4 weeks.
MIST Therapy: Non-contact low frequency ultrasound therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.0" lower_limit="34.0" upper_limit="81.0"/>
                    <measurement group_id="B2" value="58.0" lower_limit="33.0" upper_limit="86.0"/>
                    <measurement group_id="B3" value="59.0" lower_limit="33.0" upper_limit="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg per meter squared</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.2" lower_limit="21.2" upper_limit="55.7"/>
                    <measurement group_id="B2" value="37.4" lower_limit="17.2" upper_limit="69.7"/>
                    <measurement group_id="B3" value="34.7" lower_limit="17.2" upper_limit="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Wound Age at Randomization</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.9" lower_limit="1.7" upper_limit="204.5"/>
                    <measurement group_id="B2" value="10.3" lower_limit="1.5" upper_limit="114.0"/>
                    <measurement group_id="B3" value="10.3" lower_limit="1.5" upper_limit="204.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Wound Area at Randomization</title>
          <units>centimeters squared</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.8" lower_limit="2.5" upper_limit="36.9"/>
                    <measurement group_id="B2" value="12.4" lower_limit="3.1" upper_limit="53.3"/>
                    <measurement group_id="B3" value="11.0" lower_limit="2.5" upper_limit="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Wound Area Mean Percent Reduction</title>
        <description>Compare between the treatment groups percent wound area reduction at four weeks of study treatment.
H0: µMIST+SC -- µSC = 0 HA: µMIST+SC -- µSC ≠ 0 Where µ = percent reduction in wound size.</description>
        <time_frame>4 weeks post baseline visit (randomization visit)</time_frame>
        <population>eligible subjects that were randomized</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Care (SC)</title>
            <description>30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed. Minimum of one treatment per week and up to 3 times per week per investigator discretion for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>SC + Mist Therapy</title>
            <description>30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed plus non-contract low frequency ultrasound 3 x per week for 4 weeks.
MIST Therapy: Non-contact low frequency ultrasound therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Wound Area Mean Percent Reduction</title>
          <description>Compare between the treatment groups percent wound area reduction at four weeks of study treatment.
H0: µMIST+SC -- µSC = 0 HA: µMIST+SC -- µSC ≠ 0 Where µ = percent reduction in wound size.</description>
          <population>eligible subjects that were randomized</population>
          <units>percentage of mean area reduction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8" spread="32.5"/>
                    <measurement group_id="O2" value="61.6" spread="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.024</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heal Rates</title>
        <description>Compare rate of wound closure between study arms for 12 weeks post randomization. Descriptive statistics as not a powered endpoint.</description>
        <time_frame>12 weeks post randomization</time_frame>
        <population>Eligible subjects randomized</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Care (SC)</title>
            <description>30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed. Minimum of one treatment per week and up to 3 times per week per investigator discretion for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>SC + Mist Therapy</title>
            <description>30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed plus non-contract low frequency ultrasound 3 x per week for 4 weeks.
MIST Therapy: Non-contact low frequency ultrasound therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Heal Rates</title>
          <description>Compare rate of wound closure between study arms for 12 weeks post randomization. Descriptive statistics as not a powered endpoint.</description>
          <population>Eligible subjects randomized</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain VAS Scores</title>
        <description>Compare VAS Pain Scores between arms at baseline and 4 weeks post randomization
Subjects indicate their pain level by drawing a mark on a 10 cm line on a visual analog scale (VAS) at randomization and 4 week post treatment visit. The left end of the line indicates &quot;no pain&quot; and the right end of line indicates &quot;worst pain imaginable&quot;. VAS score is determined by using a ruler placed at 0 (left end of scale) and measuring the distance from zero to the patient's mark . The objective is to compare the change in VAS values in MIST+SC to SC alone.
H0: The average change in pain level is not different between MIST and SC HA: The average change in pain level is different between MIST and SC H0: µMIST = µSC vs HA: µMIST ≠ µSC,
Statistical Analysis. A repeated measures ANCOVA will be used to test for differences in change in VAS with an indicator variable to indicate treatment, any demographic variables which were significant in the baseline comparisons.</description>
        <time_frame>Baseline, 2 weeks and 4 weeks post randomization</time_frame>
        <population>Eligible Subjects Randomized</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Care (SC)</title>
            <description>30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed. Minimum of one treatment per week and up to 3 times per week per investigator discretion for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>SC + Mist Therapy</title>
            <description>30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed plus non-contract low frequency ultrasound 3 x per week for 4 weeks.
MIST Therapy: Non-contact low frequency ultrasound therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain VAS Scores</title>
          <description>Compare VAS Pain Scores between arms at baseline and 4 weeks post randomization
Subjects indicate their pain level by drawing a mark on a 10 cm line on a visual analog scale (VAS) at randomization and 4 week post treatment visit. The left end of the line indicates &quot;no pain&quot; and the right end of line indicates &quot;worst pain imaginable&quot;. VAS score is determined by using a ruler placed at 0 (left end of scale) and measuring the distance from zero to the patient's mark . The objective is to compare the change in VAS values in MIST+SC to SC alone.
H0: The average change in pain level is not different between MIST and SC HA: The average change in pain level is different between MIST and SC H0: µMIST = µSC vs HA: µMIST ≠ µSC,
Statistical Analysis. A repeated measures ANCOVA will be used to test for differences in change in VAS with an indicator variable to indicate treatment, any demographic variables which were significant in the baseline comparisons.</description>
          <population>Eligible Subjects Randomized</population>
          <units>VAS pain level measured in centimeters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Randomization (baseline) VAS Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="0.0" upper_limit="9.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="0.0" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Week post-randomizaton VAS Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0126</p_value>
            <p_value_desc>The MIST+SOC subjects decreased in their reported mean pain scores and reduced from a median of 3.0 to 0.6 cm after four weeks of study treatment.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout 12 week study</time_frame>
      <desc>Only device or study procedure related adverse events were collected in this post market study</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard Care (SC)</title>
          <description>30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed. Minimum of one treatment per week and up to 3 times per week per investigator discretion for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>SC + Mist Therapy</title>
          <description>30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed plus non-contract low frequency ultrasound 3 x per week for 4 weeks.
MIST Therapy: Non-contact low frequency ultrasound therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pamela Unger</name_or_title>
      <organization>VP Medical Affairs</organization>
      <phone>(952) 224-8755</phone>
      <email>punger@celleration.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

